Mandate

Vinge advises Axcel on its acquisition of Loopia and Active 24 from Visma

June 19, 2018 M&A

Vinge has advised the Nordic private equity firm Axcel on its acquisition of Visma’s hosting business, operating under the brands Loopia and Active 24.

Loopia and Active 24 are leading mass hosting providers and offer web domains, shared web hosting and value-added services such as security, e-commerce and Microsoft Office 365. The products are sold online on a prepaid subscription basis to around 350,000 SMEs and prosumer customers across primarily Sweden and the Czech Republic, with a further presence in Germany, Norway, the Netherlands, Serbia, Slovakia, Spain and the UK.
 
Vinge’s team consisted of partners Christina Kokko (M&A), Mikael Ståhl (Banking and Finance) and Eva Fredrikson (Commercial Agreements) together with associates Linda Sengul, Karl Klackenberg and Martin Cronsioe (M&A), Emelie Klefbeck, Josefine Larsson (Banking and Finance), Christoffer Nordin, Mathilda Persson, Isabell Nielsen, Jasmin Draszka-Ali, Lisa Hörnqvist, Moa Bodin (Commercial Agreements), Klara Secher (IP), Lova Unge, Sophia Holm (Employment), Kristoffer Larson (Real Estate), Daniel Wendelsson, Johan Wahlbom (Competition), Boris Kotur and Edin Agic (Corporate) and VDR assistant Jessica Öijer.
 

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024